Long-Term Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-Related Cirrhosis and High Liver Cell Proliferation: a Multicenter Study of Hepatocellular Carcinoma Prevention in Patients Non-Responders to Combined Therapy With Alpha Interferon + Ribavirin or Peginterferon Alpha + Ribavirin or to Interferon Monotherapy.

Trial Profile

Long-Term Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-Related Cirrhosis and High Liver Cell Proliferation: a Multicenter Study of Hepatocellular Carcinoma Prevention in Patients Non-Responders to Combined Therapy With Alpha Interferon + Ribavirin or Peginterferon Alpha + Ribavirin or to Interferon Monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Liver cancer; Liver cirrhosis
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top